P1vital® is an innovative Clinical Research Organization specializing in experimental medicine for Central Nervous System (CNS) disorders. We develop and deploy CNS efficacy biomarkers in schizophrenia, cognitive disorders, depression and anxiety, eating disorders, and obesity – with the aim of instigating innovative approaches to, and accelerating, drug research and development. P1vital Products Ltd, affiliated with P1vital Ltd, specialises in providing digital solutions for the pharmaceutical and healthcare sectors to improve the quality, compliance, timeliness and accessibility of eCOA, ePRO, and digital biomarker data collection. Our team has extensive expertise in all aspects of CNS drug discovery and development, including regulatory and compliance expertise. We are also skilled in running multi-centred academic, behavioural, and imaging clinical studies (across all phases) that require subjects with unique phenotypes. We have a strong track record of collaborating with internationally renowned opinion leaders in psychiatry and neuroscience, linked through University hospitals and clinical research facilities worldwide.
P1vital Ltd led the clinical project management of the original PRISM project and will continue this legacy in leading WP03 (Clinical study implementation and operations) for the PRISM 2 project. We also contribute to WP2 (Data management, sustainability, and analysis) and WP5 (Ethics and engagement with regulatory groups, agencies, and other stakeholders).